ID
38903
Descrizione
Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form contains information on the Spirometry which is performed at Screening, on Days 1, 2 and 28, in case of early withdrawal and as an unscheduled (repeat) assessment.
collegamento
https://clinicaltrials.gov/ct2/show/NCT01476046
Keywords
versioni (2)
- 22/10/19 22/10/19 -
- 12/11/19 12/11/19 - Sarah Riepenhausen
Titolare del copyright
GlaxoSmithKline
Caricato su
12 novembre 2019
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Phase I Trial of Intravenous TNFR1 Antagonist GSK1995057 in Healthy Subjects - NCT01476046
Spirometry
- StudyEvent: ODM
Descrizione
Dosing Date and Time
Alias
- UMLS CUI-1
- C0178602
- UMLS CUI-2
- C1264639
Descrizione
Spirometry
Alias
- UMLS CUI-1
- C0037981
Descrizione
Applicable to Day 1 only. All cohorts have to perform the predose measurement, subjects of cohort 7 additionally the 7 hours post start of infusion measurement and all other cohorts the 6 hours post start of infusion measurement.
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0439564
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Descrizione
for Repeat / Unscheduled assessments
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0037981
- UMLS CUI [1,2]
- C0449788
- UMLS CUI [1,3]
- C0242485
Descrizione
Spirometry Date/Time
Tipo di dati
datetime
Alias
- UMLS CUI [1,1]
- C0037981
- UMLS CUI [1,2]
- C1264639
Descrizione
FEV1
Tipo di dati
float
Unità di misura
- L
Alias
- UMLS CUI [1]
- C0748133
Descrizione
FVC
Tipo di dati
float
Unità di misura
- L
Alias
- UMLS CUI [1]
- C1287681
Similar models
Spirometry
- StudyEvent: ODM
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0449788 (UMLS CUI [1,2])
C0242485 (UMLS CUI [1,3])
C1264639 (UMLS CUI [1,2])